Navigating Endocrine Resistance in HR+/HER2- Breast Cancer: Novel SERDS, SERMS, and Targeted Therapies
Webinar/Online
Wednesday, July 9, 2025 at 2:00pm ET - 3:30pm ET
Add this event to your calendar
Info
Topic
Innovative targeted and biomarker-directed therapies are changing the treatment landscape in HR+/HER2- metastatic breast cancer. Differentiating between mechanisms of action and adverse event profiles for these novel agents is crucial to effectively overcome treatment challenges for patients who develop endocrine resistance. Be sure your team is at the forefront of personalizing care for patients with HR+/HER2- metastatic breast cancer. Join us for Part 3 of our Breast Cancer Hot Topics series as expert breast oncologists explore: Therapeutic mechanisms to overcome endocrine resistance, Expert strategies for incorporating biomarker assessment into clinical workflows, Nuanced treatment selection in endocrine-refractory HR+/HER2- metastatic breast cancer based on the latest evidence and guideline recommendations, Treatment considerations for novel therapies based on patient-specific factors
Credits Offered
This event offers
1.5 contact hours
to attendees.
Accreditation Info:
AANP.
Additional Information
Innovative targeted and biomarker-directed therapies are changing the treatment landscape in HR+/HER2- metastatic breast cancer. Differentiating between mechanisms of action and adverse event profiles for these novel agents is crucial.
Speakers
Betsy Bramsen Professor of Breast Oncology & Professor of Medicine
Deputy Director, Clinical Network
Director, Maggie Daley Center for Women's Cancer Care
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Professor of Hematology and Medical Oncology
Co-Director, Breast Medical Oncology
Associate Vice Chair of Faculty Development and Promotions
Winship Cancer Institute at Emory University
Atlanta, GA
Adjunct Professor
Department of Pharmacotherapy
University of Utah College of Pharmacy
Salt Lake City, UT